Clinical Trial Update: A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating PG286 ophthalmic solution 0.5% versus its components over 28 days in open-angle glaucoma and ocular hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• PG286 ophthalmic solution 0.5% (PG286)

Snippet

Sponsor: Aerie Pharmaceuticals | Conditions: Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Status: COMPLETED